Incidence and risk factors for invasive fungal infections in patients initiating TNF-alpha inhibitors for inflammatory bowel disease and rheumatoid arthritis.

Hennessee, Ian; Benedict, Kaitlin; Bahr, Nathan C; Lipner, Shari R; Gold, Jeremy A W

Hennessee, Ian; Benedict, Kaitlin; Bahr, Nathan C; Lipner, Shari R; Gold, Jeremy A W.

Afiliación

Hennessee I; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Benedict K; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Bahr NC; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Lipner SR; Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Gold JAW; Department of Dermatology, Weill Cornell Medicine, New York, New York, USA.

Clin Infect Dis ; 2024 Sep 03.

Article en En | MEDLINE | ID: mdl-39223720

ABSTRACT

ABSTRACT

In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an IFI within one year of initiating TNF-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.

Palabras clave

TNF-alpha inhibitors; biologics; candidiasis; coccidioidomycosis; histoplasmosis; immunosuppressive medications; inflammatory bowel disease; invasive fungal infections; rheumatoid arthritis; underlying medical conditions

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google